GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Debt-to-EBITDA

Inotiv (Inotiv) Debt-to-EBITDA : 17.03 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Inotiv's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $19.5 Mil. Inotiv's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $409.0 Mil. Inotiv's annualized EBITDA for the quarter that ended in Dec. 2023 was $25.2 Mil. Inotiv's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 17.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Inotiv's Debt-to-EBITDA or its related term are showing as below:

NOTV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.76   Med: 3.38   Max: 35.49
Current: 7.27

During the past 13 years, the highest Debt-to-EBITDA Ratio of Inotiv was 35.49. The lowest was -15.76. And the median was 3.38.

NOTV's Debt-to-EBITDA is ranked worse than
91.51% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.005 vs NOTV: 7.27

Inotiv Debt-to-EBITDA Historical Data

The historical data trend for Inotiv's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Debt-to-EBITDA Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.45 35.49 12.38 -1.41 -15.76

Inotiv Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 9.13 4.62 5.60 17.03

Competitive Comparison of Inotiv's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Inotiv's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Inotiv's Debt-to-EBITDA falls into.



Inotiv Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Inotiv's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(18.232 + 399.409) / -26.506
=-15.76

Inotiv's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.516 + 409.005) / 25.168
=17.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Inotiv  (NAS:NOTV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Inotiv Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Inotiv's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (Inotiv) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065